✉ Email this page to a colleague
« Back to Dashboard
Lysteda is a drug marketed by Amring Pharms and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has eight patent family members in two countries.
The generic ingredient in LYSTEDA is tranexamic acid. There are eight drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the tranexamic acid profile page.
A generic version of LYSTEDA was approved as tranexamic acid by AM REGENT on August 10th, 2011.
Summary for LYSTEDA
|Finished Product Suppliers / Packagers:||3|
|Raw Ingredient (Bulk) Api Vendors:||230|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for LYSTEDA|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for LYSTEDA|
|What excipients (inactive ingredients) are in LYSTEDA?||LYSTEDA excipients list|
|DailyMed Link:||LYSTEDA at DailyMed|
Recent Clinical Trials for LYSTEDA
Identify potential brand extensions & 505(b)(2) entrants
|Ascension Genesys Hospital||Phase 2/Phase 3|
|University of Missouri-Columbia||Early Phase 1|
|The Miriam Hospital||Phase 4|
Pharmacology for LYSTEDA
LYSTEDA is protected by eight US patents.
Patents protecting LYSTEDA
See the table below for patents covering LYSTEDA around the world.
|Country||Patent Number||Title||Estimated Expiration|
|Japan||5205053||See Plans and Pricing|
|World Intellectual Property Organization (WIPO)||2006023001||See Plans and Pricing|
|Japan||2008508276||See Plans and Pricing|
|World Intellectual Property Organization (WIPO)||2006023000||See Plans and Pricing|
|Japan||2014193878||TRANEXAMIC ACID FORMULATIONS||See Plans and Pricing|
|Japan||2011168596||TRANEXAMIC ACID FORMULATION||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|